Atypical Hemolytic Uremic Syndrome market Forecast. DelveInsight's Atypical Hemolytic Uremic Syndrome Market report offers an in-depth understanding of the ...

Atypical Hemolytic Uremic Syndrome (aHUS) is a rare but serious condition characterized by the triad of hemolytic anemia, thrombocytopenia (low platelet count), and acute kidney injury.

Sitala Bio Ltd. has prepared new indole derivatives acting as complement factor B (CFB) inhibitors. They are thus reported to be useful for the treatment of age-related macular degeneration, ...

Eculizumab is a drug that treats rare blood diseases like paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. It stops the body from destroying its own red blood cells. "The ...

Eleven people have been sickened in a severe Shiga toxin-producing E. coli (STEC) outbreak in France linked to raw milk cheese. Nine hemolytic ...

Bangalore: AstraZeneca Pharma India Limited has received permission to import pharmaceutical formulations of new drug for ...

EPYSQLI is a complement inhibitor indicated for the treatment of rare disease patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to ...

Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...

AstraZeneca Pharma India rose 1.10% to Rs 10,754 after the firm received approval from the Central Drugs Standard Control Organisation (CDSCO) to import pharmaceutical formulations of eculizumab ...

Introduction: Eculizumab is a C5 complement inhibitor approved by the FDA for the targeted treatment of four rare diseases, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic ...

Soliris (eculizumab) earned $814 million in Q2, up 16% compared to the same period last year, based on its use in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome ...